scPharmaceuticals Inc. announced that it has enrolled the first participant in the pivotal pharmacokinetic (PK) study of SCP-111 (furosemide 80 mg/mL), an investigational, low volume, pH neutral formulation of furosemide administered via an auto-injector. The auto-injector is being developed as a complement to the FDA approved On-body Infusor in an effort to provide patients with a subcutaneous injection and prescribers with treatment flexibility. If approved, the Company believes the auto-injector also has the potential to meaningfully reduce manufacturing costs.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.91 USD | -2.49% | +11.40% | -37.64% |
May. 14 | Transcript : ScPharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | ScPharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.64% | 145M | |
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+6.17% | 161B |
- Stock Market
- Equities
- SCPH Stock
- News scPharmaceuticals Inc.
- ScPharmaceuticals Inc. Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of Furoscix Auto-Injector (Furosemide 80Mg/Ml) Injection